ALIM
$4.21
Alimera Sciences
($.08)
(1.86%)
ALIM
Earnings Whisper ®
N/A
4th Quarter December 2021
Consensus:  ($0.38)
Revenue:  $13.40 Mil
Wednesday
Feb 23
7:30 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when ALIM reports earnings?
Beat
Meet
Miss

Where is ALIM's stock price going from here?
Up
Flat
Down
Stock chart of ALIM
Analysts
Summary of analysts' recommendations for ALIM
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Peers
Vertex PharmaceuticalsMerck & Co.Ultragenyx PharmaceuticalRegeneron PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisEli LillyPfizerInterCept